Crowdfunded in large part by the Epithelioid Sarcoma Community, and in need of ongoing funding!
Epithelioid Sarcoma (EPS) is a very rare soft tissue of children and adults. The underlying clinical problem is that only surgery is curative: chemotherapy and radiation are ineffective. Late relapse with metastases results in a significant unmet clinical need because surgery is not possible and effective targeted therapies have not yet been developed – until recently. Now, an EZH2 inhibitor named Tazemetostat offers responses and disease control for months at a time. The next step of our program with international collaborators is to find the type of treatments that complement Tazemetostat.
